Clinical trial
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal…
NCT00098527 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00098527 |
|---|---|
| Title | FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer |
| Official title | A Phase 2 Study of Single Agent Depsipeptide (FK228) in Gastric and Esophageal Cancers |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer |
| Intervention type | Drug, Other |
| Interventions | romidepsin, laboratory biomarker analysis |
| Enrollment | 20 |
| Start date | Oct 1, 2004 |
| Primary completion | Sep 1, 2005 |
| First posted | Dec 8, 2004 |
| Last update posted | Jul 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: